AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the Application.

LISTING OF CLAIMS:

- 1-8. (cancelled)
- 9. (currently amended) The A compound according to claim 8, of Formula IV.

$$(R^{1})_{1-2}$$
 $(R^{5})_{1-2}$
 $(R^{5})_{1-2}$
 $(R^{5})_{1-2}$

or a pharmaceutically acceptable salt thereof, wherein

X is selected from -H, $-OR^6$, $-S(O)_{0-2}R^6$, $-N(R^6)R^7$, $-O-N(R^6)R^7$, $-N(R^6)OR^6$, $-N(R^6)N(R^6)R^7$, absent, oxo, thiono, and imino, with the proviso that when X is oxo, thiono, or imino, there is only one R^1 ;

 R^1 and R^2 , at each occurance, are each independently selected from -H, halogen, -CN, -NH₂, -NO₂, -OR⁶, -N(R⁶)R⁷, -S(O)₀₋₂R⁷, -SO₂N(R⁶)R⁷, -CO₂R⁶, -C(O)N(R⁶)R⁷, -N(R⁶)SO₂R⁷, -N(R⁶)C(O)R⁷, -N(R⁶)CO₂R⁷, -C(O)R⁶, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, absent, and optionally substituted lower heterocyclylalkyl;

optionally two of R² together are oxo;

optionally, at least one pair of substituents, selected from two of R^1 , two one of R^2 , and one each of R^1 and R^2 , together with the corresponding carbon or carbons to which they are attached, form a first ring comprising between three and seven annular atoms, said first ring optionally substituted with between zero and four additional of R^1 , each

independently selected as defined above and optionally, when paired, together with the corresponding atom or atoms of the first ring to which they are attached, form a second ring comprising between three and seven annular atoms, said second ring optionally substituted with between zero and three of R¹;

R³ is selected from –H and optionally substituted lower alkyl;

R³-is selected from -H, optionally substituted lower alkyl, optionally substituted lower arylalkyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted alkoxy;

optionally R³ and one of R², together with the atoms to which each is attached, form a third ring comprising between three and seven annular atoms, said third ring optionally substituted with between zero and four additional of R¹, each independently selected as defined above and optionally, when paired, together with the corresponding atom or atoms of the third ring to which they are attached, form a fourth ring comprising between three and seven annular atoms, said fourth ring optionally substituted with between zero and three of R¹;

optionally R³ and one of R¹, together with the atoms to which they are attached and the carbon to which R² is attached, form a fifth ring comprising between three and seven annular atoms atoms, said fifth ring optionally substituted with between zero and four additional of R¹, each independently selected as defined above and optionally, when paired, together with the corresponding atom or atoms of the fifth ring to which they are attached, form a sixth ring comprising between three and seven annular atoms, said sixth ring optionally substituted with between zero and three of R¹;

m is zero to four;

each of R^4 is independently selected from -H, halogen, -CN, -NH₂, -NO₂, -OR⁶, -N(R⁶)R⁷, -S(O)₀₋₂R⁷, -SO₂N(R⁶)R⁷, -CO₂R⁶, -C(O)N(R⁶)R⁷, -N(R⁶)SO₂R⁷, -N(R⁶)C(O)R⁷, -N(R⁶)CO₂R⁷, -C(O)R⁶, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl;

n is zero to four five;

each R^5 is independently selected from -H, halogen, -CN, -NH₂, -NO₂, -OR⁶, -NR⁶R⁷, -S(O)₀₋₂R⁷, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -N(R⁶)SO₂R⁷, -N(R⁶)C(O)R⁷, -N(R⁶)CO₂R⁷, -C(O)R⁶, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower heterocyclylalkyl; and

 R^6 is -H or optionally substituted lower alkyl R^7 ;

R⁷ is selected from optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; and

R⁶ and R⁷, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl ring, said optionally substituted five- to seven-membered heterocyclyl ring optionally containing at least one additional heteroatom selected from N, O, S, and P.

- 10. (withdrawn) The compound according to claim 9, wherein X is selected from $-OR^6$, $-SR^6$, and $-N(R^6)R^7$.
- 11. (withdrawn) The compound according to claim 10, wherein two of R¹, together with the carbon or carbons to which they are attached, form said second ring.
- 12. (withdrawn) The compound according to claim 11, wherein said second ring is a six-membered aryl, fused with said first ring, said second ring optionally substituted with between zero and three of R¹.
- 13. (withdrawn) The compound according to claim 12, of formula V.

$$(R^{1})_{0-3}$$

V

- 14. (withdrawn) The compound according to claim 13, wherein X is -OR⁶.
- 15. (withdrawn) The compound according to claim 14, wherein R³ is -H.
- 16. (withdrawn) The compound according to claim 15, wherein X is -OH.
- 17. (withdrawn) The compound according to claim 16, of formula VI.

$$(R^{1})_{0-3}$$
 $(R^{5})_{n}$
 $(R^{5})_{n}$

- 18. (withdrawn) The compound according to claim 17, wherein R¹, R⁴, and R⁵ are -H.

 19-29. (cancelled)
- 30. (previously presented) A compound according to Table 3:

Table 3

#	Name	Structure
1	N-cyclohexyl-2-pyridin-4-ylquinazolin-4- amine	HN N N N N N N N N N N N N N N N N N N
3	N-cyclopentyl-2-pyridin-4-ylquinazolin-4- amine	HN—N N N 2

Table 3

#	Name	Structure
4	N-(cyclohexylmethyl)-2-pyridin-4- ylquinazolin-4-amine	HN N
7	N-[(4-fluorophenyl)methyl]-2-pyridin-4-ylquinazolin-4-amine	HN F
9	N-(2,3-dihydro-1H-inden-1-yl)-2-pyridin-4-ylquinazolin-4-amine	N N N N N N N N N N N N N N N N N N N
12	2-pyridin-4-yl-N-[(2R)-1,2,3,4- tetrahydronaphthalen-2-yl]quinazolin-4- amine	
15	2-pyridin-4-yl-N-[(2S)-1,2,3,4- tetrahydronaphthalen-2-yl]quinazolin-4- amine	HE Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z

Table 3

#	Name	Structure
18	(1S,2R)-1-[(2-pyridin-4-ylquinazolin-4-yl)amino]-2,3-dihydro-1H-inden-2-ol	HO,,,
19	1,1-dimethylethyl 4-[(2-pyridin-4-ylquinazolin-4-yl)amino]piperidine-1-carboxylate	N—N O — :
24	3-[(2-pyridin-4-ylquinazolin-4- yl)amino]naphthalen-2-ol	HO N N N N N N N N N N N N N N N N N N N
25	N-{4-[(1-methylethyl)oxy]phenyl}-2- pyridin-4-ylquinazolin-4-amine	HN N N N N N N N N N N N N N N N N N N
31	(1S,2R)-1-[(6-chloro-2-pyridin-4-ylquinazolin-4-yl)amino]-2,3-dihydro-1H-inden-2-ol	HO N NH

Table 3

#	Name	Structure
33	(1S,2R)-1-[(2-pyridin-3-ylquinazolin-4-yl)amino]-2,3-dihydro-1H-inden-2-ol	HN—N N—N—;
45	(1S,2R)-1-[(6-bromo-2-pyridin-4- ylquinazolin-4-yl)amino]-2,3-dihydro-1H- inden-2-ol	HO N NH Br
46	(1S,2R)-1-{[6,7-bis(methyloxy)-2-pyridin-4-ylquinazolin-4-yl]amino}-2,3-dihydro-1H-inden-2-ol	HO
48	(1S,2R)-1-{[2-pyridin-4-yl-7- (trifluoromethyl)quinazolin-4-yl]amino}- 2,3-dihydro-1H-inden-2-ol	HO N NH F ₃ C

Table 3

#	Name	Structure
49	(1S,2R)-1-({2-[6-(methyloxy)pyridin-3-yl]quinazolin-4-yl}amino)-2,3-dihydro-1H-inden-2-ol	HN—N N—N N—O—;
51	(1S,2R)-1-[(7-methyl-2-pyridin-4-ylquinazolin-4-yl)amino]-2,3-dihydro-1H-inden-2-ol	HN—N N—N N—N
54	(2S)-3-methyl-2-[(2-pyridin-4-ylquinazolin-4-yl)amino]butan-1-ol	N—NH OH
55	(2S)-2-phenyl-2-[(2-pyridin-4-ylquinazolin-4-yl)amino]ethanol	N OH OH
56	(2R)-2-phenyl-2-[(2-pyridin-4-ylquinazolin-4-yl)amino]ethanol	N—N—NH N—NH

Table 3

#	Name	Structure
61	(2S)-3-phenyl-2-[(2-pyridin-4-ylquinazolin-4-yl)amino]propan-1-ol	HO NH NH NH
62	2-[(phenylmethyl)(2-pyridin-4- ylquinazolin-4-yl)amino]ethanol	N OH
63	(1S,2R)-1-{[2-(2-aminopyrimidin-4-yl)quinazolin-4-yl]amino}-2,3-dihydro-1H-inden-2-ol	$HN \longrightarrow N$ $N \longrightarrow N$ H_2N
66	2-{4-[(2-pyridin-4-ylquinazolin-4-yl)amino]piperazin-1-yl}ethanol	OH N NH
67	N-piperidin-1-yl-2-pyridin-4- ylquinazolin-4-amine	

- 31. (previously presented) A pharmaceutical composition comprising the compound according to claim 9 and a pharmaceutically acceptable carrier.
- 32-38. (cancelled)